137 related articles for article (PubMed ID: 38639169)
21. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
Krackhardt F; Waliszewski M; Kočka V; Toušek P; Janek B; Hudec M; Lozano F; Roman KG; Del Blanco BG; Mauri J; Heang TM; Ahn TH; Jeong MH; Herberger D; Tomulic V; Levy G; Sebagh L; Rischner J; Pansieri M
Cardiovasc Drugs Ther; 2020 Jun; 34(3):335-344. PubMed ID: 32212061
[TBL] [Abstract][Full Text] [Related]
22. Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy.
Kedhi E; Latib A; Abizaid A; Kandzari D; Kirtane AJ; Mehran R; Price MJ; Simon D; Worthley S; Zaman A; Brar S; Liu M; Stone GW; Windecker S
Am Heart J; 2019 Aug; 214():134-141. PubMed ID: 31203158
[TBL] [Abstract][Full Text] [Related]
23. Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
Yun KH; Lee SY; Cho BR; Jang WJ; Song YB; Oh JH; Chun WJ; Park YH; Im ES; Jeong JO; Oh SK; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY;
J Am Heart Assoc; 2021 Jan; 10(1):e018366. PubMed ID: 33345567
[TBL] [Abstract][Full Text] [Related]
24. Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.
Kornowski R; Konigstein M; Jonas M; Assali A; Vaknin-Assa H; Segev A; Danenberg H; Halabi M; Roguin A; Kerner A; Lev E; Karamasis GV; Johnson TW; Anderson R; Blaxill J; Jadhav S; Hoole S; Witberg G; Issever MO; Ben-Yehuda O; Baumbach A
J Am Heart Assoc; 2024 Jan; 13(2):e029051. PubMed ID: 38214256
[TBL] [Abstract][Full Text] [Related]
25. A comprehensive meta-analysis of randomized controlled trials comparing drug-eluting stents with bare-metal stents in saphenous vein graft interventions.
Shah R; Jovin IS; Latham SB; Hesterberg K; Heckle MR; Rashid A; Vetrovec GW
Catheter Cardiovasc Interv; 2018 Dec; 92(7):1229-1236. PubMed ID: 30051628
[TBL] [Abstract][Full Text] [Related]
26. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
27. Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta-analysis of randomized primary percutaneous coronary intervention trials.
Philip F; Stewart S; Southard JA
Catheter Cardiovasc Interv; 2016 Jul; 88(1):38-48. PubMed ID: 26916633
[TBL] [Abstract][Full Text] [Related]
28. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
29. Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients.
D'Ascenzo F; Iannaccone M; Saint-Hilary G; Bertaina M; Schulz-Schüpke S; Wahn Lee C; Chieffo A; Helft G; Gili S; Barbero U; Biondi Zoccai G; Moretti C; Ugo F; D'Amico M; Garbo R; Stone G; Rettegno S; Omedè P; Conrotto F; Templin C; Colombo A; Park SJ; Kastrati A; Hildick-Smith D; Gasparini M; Gaita F
Eur Heart J; 2017 Nov; 38(42):3160-3172. PubMed ID: 29020300
[TBL] [Abstract][Full Text] [Related]
30. Optimal Stent Design for High Bleeding Risk Patients: Evidence From a Network Meta-Analysis.
Chiabrando JG; Vescovo GM; Del Buono MG; Lombardi M; Camilli M; Ravindra K; Montone RA; Niccoli G; Biondi-Zoccai G
J Invasive Cardiol; 2021 Mar; 33(3):E182-E190. PubMed ID: 33472990
[TBL] [Abstract][Full Text] [Related]
31. Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Final 2-Year Results From Onyx ONE.
Windecker S; Latib A; Kedhi E; Kirtane AJ; Kandzari DE; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Hudec M; Poliacikova P; Kahar Bin Abdul Ghapar A; Selvaraj K; Petrov I; Mylotte D; Pinar E; Moreno R; Fabbiocchi F; Pasupati S; Kim HS; Aminian A; Tie C; Wlodarczak A; Hur SH; Marx SO; Ali ZA; Parke M; Lung TH; Stone GW;
JACC Cardiovasc Interv; 2022 Jun; 15(11):1153-1163. PubMed ID: 35680195
[TBL] [Abstract][Full Text] [Related]
32. High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial.
Zocca P; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Hartmann M; Linssen GCM; Doggen CJM; von Birgelen C
Cardiovasc Drugs Ther; 2018 Dec; 32(6):567-576. PubMed ID: 30143879
[TBL] [Abstract][Full Text] [Related]
33. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
[TBL] [Abstract][Full Text] [Related]
34. Major ischaemic and bleeding risks following current drug-eluting stent implantation: Are there differences across current drug-eluting stent types in real life?
Schapiro-Dufour E; Tricotel A; Slama MS; Ducimetière P; Trinh-Duc A; Sichel C; Le Tri T; Galmiche H; Dray-Spira R; Zureik M
Arch Cardiovasc Dis; 2019; 112(8-9):469-484. PubMed ID: 31262635
[TBL] [Abstract][Full Text] [Related]
35. Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.
Wang HY; Dou KF; Yin D; Zhang D; Gao RL; Yang YJ
BMC Cardiovasc Disord; 2020 Jul; 20(1):313. PubMed ID: 32611318
[TBL] [Abstract][Full Text] [Related]
36. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
[TBL] [Abstract][Full Text] [Related]
37. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
38. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.
Sorrentino S; Sartori S; Baber U; Claessen BE; Giustino G; Chandrasekhar J; Chandiramani R; Cohen DJ; Henry TD; Guedeney P; Ariti C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Urban P; Mehran R
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008226. PubMed ID: 32216472
[TBL] [Abstract][Full Text] [Related]
39. Comparison of outcomes in patients with or without ARC-HBR criteria undergoing PCI with polymer-free biolimus coated stents: The BioFreedom France study.
Garot P; Brunel P; Dibie A; Morelle JF; Abdellaoui M; Levy R; Carrié D; Karsenty B; Robin C; Berland J; Copt S; Sadozai Slama S; Oldroyd K; Morice MC; Lipiecki J;
Catheter Cardiovasc Interv; 2023 Jan; 101(1):60-71. PubMed ID: 36378683
[TBL] [Abstract][Full Text] [Related]
40. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.
Chandrasekhar J; Kok MM; Kalkman DN; Aquino MB; Zocca P; Woudstra P; Beijk MA; Kerkmeijer LS; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Pocock S; von Birgelen C; Mehran R; de Winter RJ;
JACC Cardiovasc Interv; 2020 Apr; 13(7):820-830. PubMed ID: 32273094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
